Form 4: Harvard Bioscience Director Awarded 110,000 Restricted Stock Units

Harvard Bioscience Inc. Director Robert E. Gagnon was granted 110,000 restricted stock units, aligning his interests with shareholders.

Summary

• Robert E. Gagnon, a Director of Harvard Bioscience Inc. (HBIO), was awarded 110,000 restricted stock units (RSUs).
• The transaction date for this acquisition is July 16, 2025.
• The RSUs were granted at a price of $0.00 per unit.
• These RSUs will fully vest on the earlier of two conditions: the date of the Issuer's next Annual Meeting of Stockholders after July 16, 2025, or July 16, 2026.
• Following this transaction, Mr. Gagnon beneficially owns 110,000 shares directly.

Sentiment

Score: 7

Explanation: The award of restricted stock units to a director is generally a positive sign of alignment between management and shareholders, indicating a commitment to long-term value creation. While it implies future dilution, this is a standard and expected aspect of equity compensation.

Positives

• The award of restricted stock units to a director aligns management's interests with those of shareholders, as the value of the award is tied to the company's stock performance.
• This type of equity compensation is a common practice to incentivize long-term commitment and performance from key personnel.

Negatives

• The future vesting of these restricted stock units will result in dilution of existing shares when they convert to common stock, although this is a standard aspect of equity compensation plans.

Future Outlook

The 110,000 restricted stock units awarded to Director Robert E. Gagnon are set to fully vest on the earlier of the Issuer's next Annual Meeting of Stockholders after July 16, 2025, or July 16, 2026, indicating a future conversion of these units into common stock.

Industry Context

The granting of restricted stock units to directors is a common practice across various industries, particularly in the biotechnology and life sciences sectors where long-term innovation and strategic oversight are critical. This type of equity compensation is widely used to attract, retain, and motivate key leadership by aligning their financial interests with the company's long-term performance and shareholder value creation.

Comparison to Industry Standards

• The award of 110,000 restricted stock units to a director is a standard form of equity compensation.
• While the specific number of units varies by company size, industry, and individual role, RSU grants are a prevalent mechanism for incentivizing long-term commitment and performance.
• Similar practices are observed in companies like Thermo Fisher Scientific (TMO) or Danaher Corporation (DHR), where executive and director compensation packages frequently include significant RSU components to foster alignment with shareholder interests and encourage sustained growth.
• The $0.00 acquisition price is typical for such awards, reflecting their nature as a grant rather than a purchase.

Related Party Transactions

• The award of 110,000 restricted stock units to Robert E. Gagnon, a Director of Harvard Bioscience Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: Potential minor future dilution upon vesting of RSUs, but also increased alignment of a director's interests with long-term shareholder value.

Next Steps

• The restricted stock units will vest on the earlier of the Issuer's next Annual Meeting of Stockholders after July 16, 2025, or July 16, 2026.
• Upon vesting, the restricted stock units will convert into common stock, increasing Robert E. Gagnon's direct beneficial ownership of Harvard Bioscience Inc. shares.

Key Dates

Recommendation

Keywords

Harvard Bioscience, HBIO, Robert E. Gagnon, Restricted Stock Units, RSU, Equity Compensation, Director Compensation, SEC Form 4, Insider Transaction, Stock Award, Corporate Governance